For the tentative first week of March webcast for Resverlogix, I am doubtful we will hear anything regarding Zenith, since we just had a Zenith Q1 Corporate update last month. From what we were told by Zenith in January, the Phase 1 Prostate Cancer trial start is imminent (H1 2016). From Resverlogix I would like to hear updates on (commence brainstorm):

1) Status of BETonMACE study site activation and enrollment. Hard to tell from ClinicalTrials.gov or EU Clinical Trials register what the actual status is since these are updated very infrequently.

2) Timeline and launch of the RVX-208 Phase 2 PNH trial. Is a H1 2016 trial start still a possibility?

3) Number of and timeline for other RVX-208 orphan disease trials as alluded to in the recent blog video. Will these happen concurrent with the PNH trial? How will these be funded?

4) Plans for Alzheimer's trial that seems to keep getting kicked down the road. In the September Corporate Update they discussed how the complement pathway is now being appreciated to be involved in Alzheimer's progression, so seems like there should be renewed interest.

5) Collaboration with university in Colorado (can't remember which one) to analyze up to 1300 plasma proteins in the ASSERT trial samples. Ewalina Kulikowski talked about this in the September Corporate Update.

6) Plans for RVX-208 follow on molecules. Will these be for MACE/Athero or other indications? What kind of pre-clinical data has been collected on these?

7) Plans for Nasdaq listing

8) Licensing deals

9) Status of Hepalink agreement. For example, will they still have patients in BETonMACE? How is China econony affecting things if at all?

10) How are discussion with FDA for BETonMACE going? Still ongoing? Finished? Any chance for US study sites/patients in BETonMACE?

11) Conferences planning to attend in 2016

12) Scientific manuscripts in preparation

13) Estimate for when the BETonMACE 125 event interim analysis might occur

Brainstorm off.

BearDownAZ